Sequenom's Q2 Loss Narrows 35 Percent as Revenue Rises and R&D Spend Drops | GenomeWeb
NEW YORK (GenomeWeb News) – Sequenom today said second-quarter net loss narrowed on a 15-percent increase in revenues and reduced R&D spending.
The results caused shares in the company to trade up 6.9  percent, or $.11, at $1.70 mid-afternoon today.
Receipts for the three months ended June 30 increased to $7 million from $6 million year over year.
R&D costs declined almost 20 percent to $2.4 million from $3 million from the comparable quarter a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.